3SBio Inc. (HKG:1530)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development, Production, Marketing and Sale of Biopharmaceutical Products	17.70B	9.11B	7.82B	6.87B	6.38B
Development, Production, Marketing and Sale of Biopharmaceutical Products Growth	94.29%	16.53%	13.84%	7.58%	14.22%
Total	17.70B	9.11B	7.82B	6.87B	6.38B
Total Growth	94.29%	16.53%	13.84%	7.58%	14.22%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Mainland China	7.91B	8.85B	7.60B	6.66B	6.24B
Mainland China Growth	-10.63%	16.48%	14.14%	6.67%	15.13%
Usa	9.52B	1.08M	-	-	-
Usa Growth	883442.90%	-	-	-	-
Others	270.43M	256.21M	217.43M	208.75M	141.09M
Others Growth	5.55%	17.83%	4.16%	47.96%	-15.36%
Total	17.70B	9.11B	7.82B	6.87B	6.38B
Total Growth	94.29%	16.53%	13.84%	7.58%	14.22%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 26, 2026

Data Sources Report a data error